SCM
ACRS icon

Sio Capital Management’s Aclaris Therapeutics ACRS Stock Holding History

Sio Capital Management’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-138,441
Closed -$3.76M – 48
2016
Q4 		$3.76M Buy
+138,441
New +$3.53M 2.19% 20

Other funds holding ACRS

VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
SMV
Sofinnova Management VIII Menlo Park, California $183M AUM 4.18% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
PC
PointState Capital New York $7.82B AUM 43.51% 1-Year Est. Return
PC
Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Sio Capital Management's ACRS Position: Q1 2017 in Review

Sio Capital Management sold out of Aclaris Therapeutics (ACRS) in Q1 2017, closing a stake of 138,441 shares — an estimated $3.76M sold.

Sio Capital Management first reported a position in ACRS in Q4 2016 and held it in 1 quarter. The position peaked at $3.76M in Q4 2016. 110 funds tracked by Wall St. Rank hold ACRS as of Q1 2017.

  • Sio Capital Management reported no remaining Aclaris Therapeutics position as of Q1 2017 after selling out during the quarter.
  • Sio Capital Management sold 138,441 Aclaris Therapeutics shares in Q1 2017, an estimated $3.76M.
  • Sio Capital Management first reported a position in Aclaris Therapeutics in Q4 2016 and held it in 1 quarter.
  • Sio Capital Management's Aclaris Therapeutics position peaked at $3.76M in Q4 2016.
  • 110 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q1 2017.

Based on Sio Capital Management's 13F filing for Q1 2017, filed 15 May 2017.